Real-‎World Evidence Collaborative

(SLC-048) Association between COVID-19 and thrombotic events: using Super Learner algorithm combined with doubly robust methods.

(SLC-042) Characterizing Neuropsychiatric Adverse Events of Semaglutide Reported in FAERS: Analysis of Off-Label and On-Label Use

(SLC-047) EU-Wide Survey on Key Stakeholders’ Knowledge, Opinions and Interests on Real-World Evidence in the Regulatory Process

(C-203) Incorporation of Tokenized Real-World Data into a Phase 4 Vaccine Effectiveness Study: Assessment of Feasibility and Utility

(C-205) Integrate Real-World Data and Genetics: A Causal Machine Learning Approach to Assess Heterogeneous Treatment Effect of Statins on Alzheimer's Disease

(SLC-045) Mapping the Overall Safety Profile of Levothyroxine-Related Adverse Events: a Disproportionality Analysis on Individual Case Safety Reports Collected by the FAERS

(SLC-046) Real-World Effectiveness of Osteoporosis Medications in Reducing Fracture Rates Among Men

(SLC-041) Remdesivir and Renal Outcomes in Hospitalized COVID-19 Patients Without Severe Renal Impairment: A Retrospective Cohort Study

(SLC-043) Utilization of Real-World Evidence in Drug Approvals at the European Medicines Agency from 2020 to 2023

(SLC-044) Validity of German ICD-10-GM Diagnosis Codes for Myocardial Infarction against Chart Review of Electronic Health Records